HCW Biologics Inc. Operating Cash Flow
HCW Biologics Inc. (HCWB) reported Operating Cash Flow of -$5.54 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- HCW Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.97M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$1.58M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.36M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.24M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$13.39M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$14.23M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$22.51M.
- HCW Biologics Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$10.39M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.97M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-14 | -$5.54M 10-Q · filed 2026-08-14 | -$8.90M derived: sum of 3 quarters · filed 2026-08-14 | -$12.14M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$1.58M 10-Q/A · filed 2026-08-14 | -$4.93M derived: sum of 2 quarters · filed 2026-08-14 | -$8.17M derived: sum of 3 quarters · filed 2026-08-14 | -$11.45M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$6.60M derived: sum of 2 quarters · filed 2026-03-31 | -$9.88M derived: sum of 3 quarters · filed 2026-08-14 | -$13.39M 10-K · filed 2026-03-31 |
| 2025-09-30 | -$3.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$6.52M derived: sum of 2 quarters · filed 2026-08-14 | -$10.04M 10-Q · filed 2025-11-14 | -$12.87M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-14 | -$6.80M 10-Q · filed 2026-08-14 | -$9.63M derived: sum of 3 quarters · filed 2026-08-14 | -$12.56M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$3.51M 10-Q/A · filed 2026-08-14 | -$6.35M derived: sum of 2 quarters · filed 2026-08-14 | -$9.28M derived: sum of 3 quarters · filed 2026-08-14 | -$14.14M derived: sum of 4 quarters · filed 2026-08-14 |
| 2024-12-31 | -$2.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$5.76M derived: sum of 2 quarters · filed 2026-03-31 | -$10.62M derived: sum of 3 quarters · filed 2026-03-31 | -$14.23M 10-K · filed 2026-03-31 |
| 2024-09-30 | -$2.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$7.79M derived: sum of 2 quarters · filed 2025-11-14 | -$11.39M 10-Q · filed 2025-11-14 | -$15.29M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$4.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$8.47M 10-Q · filed 2025-08-18 | -$12.36M derived: sum of 3 quarters · filed 2025-08-18 | -$17.95M derived: sum of 4 quarters · filed 2025-08-18 |
| 2024-03-31 | -$3.60M 10-Q · filed 2025-05-15 | -$7.50M derived: sum of 2 quarters · filed 2025-05-15 | -$13.09M derived: sum of 3 quarters · filed 2025-05-15 | -$22.48M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$3.89M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | -$9.48M derived: sum of 2 quarters · filed 2025-03-28 | -$18.88M derived: sum of 3 quarters · filed 2025-03-28 | -$22.51M 10-K · filed 2025-03-28 |
| 2023-09-30 | -$5.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$14.98M derived: sum of 2 quarters · filed 2024-11-14 | -$18.62M 10-Q · filed 2024-11-14 | -$22.41M derived: sum of 4 quarters · filed 2024-11-14 |
| 2023-06-30 | -$9.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | -$13.03M 10-Q · filed 2024-08-14 | -$16.82M derived: sum of 3 quarters · filed 2024-08-14 | -$19.13M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$3.64M 10-Q · filed 2024-05-15 | -$7.43M derived: sum of 2 quarters · filed 2024-05-15 | -$9.74M derived: sum of 3 quarters · filed 2024-05-15 | -$12.43M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | -$3.79M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-05-15 | -$6.10M derived: sum of 2 quarters · filed 2024-05-15 | -$8.79M derived: sum of 3 quarters · filed 2024-05-15 | -$10.39M 10-K/A · filed 2024-05-15 |
| 2022-09-30 | -$2.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$5.00M derived: sum of 2 quarters · filed 2023-11-14 | -$6.60M 10-Q · filed 2023-11-14 | -$9.97M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$2.69M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-08-11 | -$4.28M 10-Q · filed 2023-08-11 | -$7.66M derived: sum of 3 quarters · filed 2023-08-11 | -$12.78M derived: sum of 4 quarters · filed 2023-08-11 |
| 2022-03-31 | -$1.59M 10-Q/A · filed 2023-08-10 | -$4.97M derived: sum of 2 quarters · filed 2023-08-10 | -$10.09M derived: sum of 3 quarters · filed 2023-08-10 | -$11.08M derived: sum of 4 quarters · filed 2023-08-10 |
| 2021-12-31 | -$3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | -$8.50M derived: sum of 2 quarters · filed 2023-03-28 | -$9.49M derived: sum of 3 quarters · filed 2023-03-28 | -$10.98M 10-K · filed 2023-03-28 |
| 2021-09-30 | -$5.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$6.11M derived: sum of 2 quarters · filed 2022-11-07 | -$7.60M 10-Q · filed 2022-11-07 | -$11.14M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$990.44K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$2.48M 10-Q · filed 2022-08-12 | -$6.02M derived: sum of 3 quarters · filed 2022-08-12 | -$8.77M derived: sum of 4 quarters · filed 2022-08-12 |
| 2021-03-31 | -$1.49M 10-Q · filed 2022-05-13 | -$5.03M derived: sum of 2 quarters · filed 2022-05-13 | -$7.78M derived: sum of 3 quarters · filed 2022-05-13 | |
| 2020-12-31 | -$3.54M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$6.29M derived: sum of 2 quarters · filed 2022-03-29 | -$10.43M 10-K · filed 2022-03-29 | |
| 2020-09-30 | -$2.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$6.89M 10-Q · filed 2021-11-12 | ||
| 2020-06-30 | -$4.14M 10-Q · filed 2021-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| Onconetix, Inc. (ONCO) | United States | $0.004B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |